Matignon Investissement et Gestion

Matignon Investissement et Gestion is an independent management company based in Paris, France, founded in 1996. It specializes in venture capital investments and is registered with the Autorité des Marchés Financiers, which is the French equivalent of the Securities and Exchange Commission. The firm is also a member of the French Association of Capital Investors and the European Venture Capital Association, reflecting its commitment to industry standards and practices. Matignon Investissement et Gestion focuses on providing strategic capital to support the growth of innovative companies, leveraging its expertise to identify and nurture promising investment opportunities.

Thierry Chignon

Partner

6 past transactions

Guard Medical

Series B in 2022
Guard Medical is a medical device company that specializes in developing innovative solutions for wound care. Its primary product, NPseal™, is designed for prophylactic negative pressure wound therapy (NPWT) of closed surgical incisions. This device aims to reduce surgical site infections and improve the healing process by establishing and maintaining negative pressure with minimal effort. By integrating an easy-to-use pump, NPseal™ allows patients to effectively prevent infection and minimize scarring, ultimately enhancing the cosmetic outcomes of surgical wounds. The company focuses on creating cost-effective alternatives that prioritize patient care and recovery.

AirInSpace

Series B in 2007
AirInSpace specializes in the development, manufacturing, and distribution of mobile and in-duct air purification systems designed for the healthcare sector, aerospace, and various industries. Their HEPA-MD reactor system, utilized in products like plasmair T2006 and immunair, effectively filters and inactivates a wide range of airborne biological particles. Since its inception in 2005, AirInSpace has deployed over 350 devices across more than 100 hospitals globally. Notably, the same technology is employed on the International Space Station to safeguard astronauts and equipment. The company is recognized for its commitment to quality, operating as an ISO 9001 certified manufacturing facility.

Gentis

Series A in 2007
Gentis is a developer of minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spine. The company's patented product is DiscCell, an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material that augments or replaces the diseased nucleus pulposus of the spinal disc. Gentis was founded on 2000 and is headquartered in Wayne, Pennsylvania.

Nautilus Biotech

Venture Round in 2007
Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

Nautilus Biotech

Venture Round in 2005
Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

OSMOS Group

Venture Round in 2001
OSMOS Group offers optimizes maintenance to save energy and materials needed for new construction. They provide facility managers and engineering and construction companies the possibility of monitoring the evolution of their structures continuously and in real-time.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.